NEW YORK (GenomeWeb) – Foundation Medicine said last week that orders for its NGS-based tumor profiling tests — FoundationOne and FoundationOne Heme — continue to rise, both among the academic medical community as well as among community oncologists. It has also received unique identifiers for its tests from the online test registry McKesson Diagnostics Exchange, which it said would help in obtaining reimbursement for its tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.